News & Events about Athersys Inc.
Business Wire
5 months ago
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Cares (CTTACC) conference, Cellular Therapies and Transfusion...
Business Wire
5 months ago
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL. The...
Ticker Report
6 months ago
StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX Get Rating) in a research report report published on Thursday. The brokerage issued a sell rating on the biopharmaceutical companys stock. Separately, Alliance Global Partners started coverage on shares of Athersys in...
Business Wire
7 months ago
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA). The Company was...
Business Wire
8 months ago
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer...